The Australian biotechs racing toward the next billion dollar cancer drug
Arovella CEO and MD, Dr Michael Baker was recently interviewed for a Forbes Australia article about the company’s iNKT cell therapy.
There’s a revolution going on in cancer treatment with more than 1,000 clinical trials underway into CAR-T therapies promising an immune response up to 1,000 times stronger than ordinary immune cells. Chasing a market worth billions, we take a look at three Australian biotechs with their elbows out.